Simoctocog Alfa
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Simoctocog Alfa: From Hemophilia A to Pseudo-von Willebrand Disease
One-Sentence Summary
Simoctocog alfa is a recombinant, B-domain-deleted Factor VIII (FVIII) product used for the prevention and treatment of bleeding in Hemophilia A. The TxGNN model predicts it may be effective for Pseudo-von Willebrand Disease, but this is currently a model prediction only — there are 0 clinical trials and 0 publications supporting this direction, and the accompanying mechanistic review flags the biological rationale as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hemophilia A — bleeding prophylaxis/treatment and surgical hemostasis (no approved-label text available; inferred from evidence-pack rationale, not from regulatory license data) |
| Predicted New Indication | Pseudo-von Willebrand Disease |
| TxGNN Prediction Score | 99.997% |
| Evidence Level | L5 (no clinical trials, no literature) |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on information embedded elsewhere in this pack’s own rationale text, simoctocog alfa is a recombinant B-domain-deleted FVIII product approved for Hemophilia A, where it replaces deficient circulating Factor VIII to restore the intrinsic coagulation cascade.
For the top-ranked prediction, however, this mechanism does not transfer well. Pseudo-von Willebrand Disease is caused by a gain-of-function defect in the platelet GPIb receptor, which leads to excessive platelet binding and clearance of von Willebrand Factor. The underlying problem is on the platelet side, not a deficiency of coagulation factor concentration — supplementing FVIII does not correct this platelet–VWF interaction defect. The evidence pack’s own repurposing rationale explicitly notes that the very high TxGNN score for this candidate likely reflects graph-level proximity of “bleeding disorder” nodes in the knowledge graph, rather than a genuine pharmacological relationship.
Notably, two lower-ranked candidates in this pack show more plausible mechanistic links and have been advanced to decision stage S1 (“Research Question”) rather than held at S0: acquired coagulation factor deficiency (rank 5) and Hemophilia A with vascular abnormality (rank 9). The latter in particular remains within the FVIII-deficiency disease spectrum and is closer to an indication extension than a true repurposing signal, though it still lacks any supporting trial or literature evidence. These may warrant closer attention than the current rank-1 candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EMA marketing authorization is recorded for this product in the current dataset (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the SmPC for safety information. All key warnings, contraindications, and drug-interaction data for this product are currently unavailable in this evidence pack (DG001, flagged Blocking severity — this gap alone prevents progression to the S1 safety review stage).
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Pseudo-von Willebrand Disease) has no supporting clinical trials or literature and is accompanied by an internal mechanistic assessment indicating the pharmacology is unlikely to apply. Combined with a blocking safety data gap (no SmPC warnings/contraindications available) and the product’s current lack of EU marketing authorization in this dataset, there is insufficient basis to proceed.
To proceed, the following is needed:
- TFDA/EMA product label (SmPC) with warnings and contraindications, to close the blocking safety gap (DG001)
- Confirmed mechanism-of-action data via DrugBank API (DG002)
- If pursuing repurposing further, prioritize the mechanistically closer, S1-stage candidates — acquired coagulation factor deficiency and Hemophilia A with vascular abnormality — over the current rank-1 candidate, and conduct a targeted literature/trial search for FVIII use in acquired hemophilia A (noting that inhibitor-positive patients typically require bypassing agents rather than direct FVIII replacement)
- Confirmation of EU marketing authorization status, since the dataset currently shows 0 licenses
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.